Exploit Understanding of TGF-β Biology, Harness Clinically Validated Biomarkers & Advance Safe & Efficacious Clinical Programs for Maximal Therapeutics Benefit in Immuno-Oncology. In the past year alone, the field has learnt valuable lessons from the clinical trials and from the wider TGF-β field that will equip the immuno-oncology field with the knowledge needed to supercharge […]

Over the last few decades, immunotherapy has developed at a rapid rate in the treatment of cancer where neoantigens are the latest breakthrough in tumour immunotherapy. Today, it is still unclear when a cancer vaccine will be made commercially available; what is the latest academic research showing us? What is the industry missing and where […]

6th Annual 3D Cell Culture Conference 8-9 February 2022 London, UK http://www.3D-cellculture.com/PJwl Sponsored: CelVivo, Promega and Systemic Bio Conference Co-chairs: Phillip Hewitt, Global Head of Early Investigative Toxicology, Merck Rhiannon David, Director, Microphysiological Systems, AstraZeneca  Exploring the implementation of complex in-vitro models for drug development Join us in February 2023, as SAE Media Group’s 6th annual […]

SAE Media Group invites you to join the 14th Annual RNA Therapeutics Conference, taking place on 8 and 9 February 2023, in London, UK. Building on the success of previous years, the RNA Therapeutics Conference will bring together industry experts from leading pharma and biotech companies to provide an expert and holistic view on the […]

Introducing the only industry forum exclusively bringing together key decision-makers, within health insurers and providers, who are responsible for payment and revenue integrity, value-based payment, and networking relations. At a time when both payers and providers are evaluating and streamlining internal payment and revenue integrity processes, this networking conference has been established to breakdown silos, […]

The 5th Annual CRISPR AgBio Congress will unite research heads, molecular biologists, regulatory experts, and product developers from large Ag companies, innovative AgBiotechs, academic groups and regulatory bodies to translate share the challenges and opportunities of translating cutting-edge CRISPR technology into a tangible product. If you are working to advance genome-edited crops or plants, this […]

Retinal Vascular Disease Drug Development Summit is an event dedicated to creating a community space dedicated to overcoming the current challenges in drug development for retinal vascular diseases. The management of these diseases has made remarkable advancements in previous years, but the burden on patients remains high, posing a need to develop novel therapeutics and […]

Welcome to the 11th Alzheimer’s & Parkinson’s Drug Development Summit With a surge in preclinical investment, fresh news of clinical pipeline progressions, and a new era of therapies pending FDA approvals from Biogen, Eisai, and Denali Therapeutics, 2022 has put neurodegenerative drug development back on the map. Building on the field’s momentum, we are delighted to bring back the 11th Alzheimer’s […]

 Join us in London this February to connect with those trailblazing the next wave of CAR and TCR based approaches from pre-clinical development with in vivo engineering and regulatory fast-track strategies to streamlined analytics and automation to make CAR and TCR therapies better, and faster. Take advantage of cutting-edge innovation from global biopharma leaders in cell armouring, combination approaches and multiplexing gene engineering to improve cell durability and trafficking […]

The past twelve months have seen an unprecedented level of excitement, investment, and progression within the gene therapy for muscular disorders field. As the industry endeavours to move gene therapy treatment through the preclinical and clinical pipeline, in context of reducing toxicity and increasing efficacy, attending the 3rd Annual Gene Therapy for Muscular Disorders Summit […]

Since Kinase inhibitors have proven to be efficacious and approvable targets, fuelling recent investment into this exciting space as their therapeutic targeting is explored beyond oncology. However, increasing resistance to existing programs and safety bottlenecks threaten further progress. The next wave of kinase targets depends on innovation. Join the 2nd Next Generation Kinase Inhibitors Summit to connect […]